Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For? : Kidney360

Journal Logo


Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Transplantation: What Are We Waiting For?

Patel, Niralee1; Hindi, Judy2; Farouk, Samira S.2

Author Information
Kidney360 2(7):p 1174-1178, July 2021. | DOI: 10.34067/KID.0000732021
  • Free


In recent robust randomized control trials (RCTs), sodium-glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) have been shown to dramatically decrease both kidney and cardiovascular (CV) adverse outcomes in patients with diabetic kidney disease, nondiabetic proteinuric kidney disease, and heart failure with reduced ejection fraction—with and without the presence of diabetes (1–6). For decades, both the nephrologist’s and transplant nephrologist’s arsenal for the management of proteinuric kidney disease has been limited to renin-angiotensin-aldosterone system blockade (7). Although SGLT2 inhibitors have taken the nephrology community by storm, patients with kidney transplants (KTs) have been notably excluded from large RCTs (8–10). Pathophysiologically, it seems likely they would also benefit from these apparent wonder drugs, particularly as many patients with KT have proteinuric kidney disease or heart failure. Similar to patients with native kidney disease, CV mortality is the leading cause of death in the KT population (11). Is it time to allow patients with KT to benefit from proposed SGLT2 inhibitor mechanisms, including tubuloglomerular feedback restoration, decreased inflammation and fibrosis, and alteration in energy metabolism, that all culminate in improved CV and kidney outcomes (12)? Here, we review the available data for SGLT2 inhibitor use in patients with KTs and discuss potential benefits and risk of their use in this population.

CV and Native Kidney Outcomes

Since 2015, sequential RCTs have demonstrated efficacy of SGLT2 inhibitors in improving both kidney and CV outcomes. A 2020 meta-analysis included six of these RCTs that studied SGLT2 inhibitor use (empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin) in close to 47,000 patients with diabetes (2). In all of the studies included in the meta-analysis, SGLT2 inhibitor use led to a reduction in heart failure hospitalizations, with empagliflozin being the only drug with significant CV death risk reduction. A reduction in kidney outcomes was seen with all agents except ertugliflozin, despite its similar pharmacology to other drugs in the class.

Via selective SGLT2 cotransporter inhibition in the proximal convoluted tubule, these medications inhibit filtered glucose reabsorption. Interestingly, early SGLT2 inhibitor RCTs, CANVAS and EMPA-REG, reported a mean glycated hemoglobin (HbA1c) improvement of only 0.5%–0.6% (3,4). Thus, the mechanism portending favorable CV and nephroprotective effects of SGLT2 inhibitors extends well beyond the antiglycemic effects and includes the restoration of tubuloglomerular feedback and natriuretic effects as well as proposed direct effects on myocardial tissue and the pathogenesis of fibrosis (13).

Early RCT results suggested positive kidney effects of SGLT2 inhibitors; however, the primary end points of these studies were CV and not kidney outcomes (4,8). Moreover, they included patients with mean eGFR of 75 ml/min per 1.73 m2, and only 8%–11% of patients had albuminuria. The 2019 CREDENCE trial included 4400 patients with type 2 diabetes and albuminuria with CKD (eGFR 30–89 ml/min per 1.73 m2) and showed a 30% relative risk reduction (P<0.001) in ESKD, doubling of the serum creatinine, or kidney or CV death with the use of canagliflozin as compared with placebo (9). This study also showed a mean 31% decrease in albuminuria (5). Serious adverse events were not seen in patients on canagliflozin. More recently, the DAPA-CKD trial showed improved kidney outcomes with dapagliflozin in patients with and without diabetes, CKD (eGFR>25 ml/min per 1.73 m2), and albuminuria (6). This study showed an improved primary composite outcome (≥50% eGFR decline, new ESKD, or kidney or CV mortality) in the dapagliflozin group compared with placebo (hazard ratio, 0.61; 95% confidence interval, 0.51 to 0.72; P<0.001).

Although exclusion criteria of previous RCTs have been limited, those with KT on immunosuppressants have not been included. Further, patients with KT have a high prevalence of diabetes and CV disease, with subsequent overall morbidity and mortality (11).

Potential Risks of SGLT2 Inhibitor Use in Patients with KT

Clinical studies have clearly showcased the benefits of SGLT2 inhibitors but have simultaneously been accompanied by concern for urinary tract infection (UTI), AKI, genital infections including both mycotic and Fournier gangrene, lower-extremity amputations, and euglycemic ketoacidosis (Figure 1) (14).

Figure 1.:
Reported adverse effects associated with sodium-glucose cotransporter 2 inhibitor (SGLT2i) use include euglycemic diabetic ketoacidosis, limb amputation, AKI, UTI, and genital infections. This figure was created with DKA, diabetic ketoacidosis; UTI, urinary tract infection.

Infectious Risks

Infection clearly raises additional concern for patients with KT on immunosuppression. These patients are at increased risk of bacterial and fungal infections, particularly earlier in the post-transplantation period, due to the risk of leukopenia from immunosuppressant use coupled with concomitant viral prophylaxis (15). SGLT2 inhibitor–induced glucosuria may provide a substrate for bacteria and fungi growth and increase the risk of urogenital infections, including potentially life-threatening Fournier gangrene (necrotizing fasciitis of the perineum). Of note, a recent study found that treatment with SGLT2 inhibitors, when compared with treatment with two or more non-SGLT2 inhibitor antihyperglycemic agents or insulin alone, was not associated with an increased risk of hospitalization for Fournier gangrene (16).

Although RCTs have not shown a significantly increased risk of UTI associated with SGLT2 inhibitor use, UTIs already present a significant challenge in patients with KT as the most common infectious complication that accounts for 30% of hospitalizations for sepsis (17). Even without the use of SGLT2 inhibitors, approximately one-quarter of transplant recipients develop a UTI within the first year of transplant. Risk factors include female sex, history of frequent UTIs prior to transplantation, urologic abnormalities, and ureteral stent use (18). Similarly, SGLT2 inhibitor–induced glucosuria has been associated with an increased risk of mycotic genital infection (candida vaginitis, vulvovaginitis, or balanitis), with increased risk reported for women and those with a history of prior infection (14). Compared with individuals enrolled in these studies, patients with KT differ in both their genitourinary anatomy and use of chronic immunosuppression, thus begging the question of whether SGLT2 inhibitors will lead to a more pronounced adverse effect profile in this population.

Noninfectious Risks

As in the non-KT population, AKI, ketoacidosis, and distal limb amputations present potential risks for patients with KTs. Physiologically, SGLT2 inhibitors cause afferent arterial vasoconstriction and subsequently, can precipitate an acute drop in GFR (8,9). This reduction in GFR, coupled with the natriuretic and diuretic effect, has led to concern that SGLT2 inhibitors can increase the risk of hemodynamic AKI. It is plausible that this effect may be more profound in the early post-transplantation period, particularly when polyuria is common. In patients without KT, a recent meta-analysis of over 150,00 patients found that regardless of the type of SGLT2 inhibitor used, the odds of AKI were actually lower in the treatment group (19). Reports of euglycemic ketoacidosis have underscored the importance of SGLT2 inhibitor avoidance in those with type 1 diabetes as well as during episodes of illness. Further, patients with KT are already at increased risk of diabetic ketoacidosis, which has been associated with higher mortality (20). Although an increased risk of lower-extremity amputation was seen in CANVAS with canagliflozin use, subsequent studies of both canagliflozin and other SGLT2 inhibitors suggest that this is not a class effect (2,9,10).

Efficacy and Safety of SGLT2 Inhibitors in Patients with KT: What We Know

Although large-enough studies have not yet been completed to answer the question of long-term efficacy, limited studies have begun to try to answer that of short-term efficacy and safety of SGLT2 inhibitors in patients with KT and type 2 diabetes. These studies, consisting of one small RCT, patient series, and retrospective analyses, are summarized in Table 1. As has been reported in non-KT SGLT2 inhibitor clinical trials, patients with KTs also experienced only modest improvements in glycemic control.

Table 1. - Summary studies of patients with kidney transplants and sodium-glucose cotransporter 2 inhibitor use
Author (Drug) Design Sodium-Glucose Cotransporter 2, n Control/Reference Group, n Urinary Tract Infection Genital Mycotic Infection Other Adverse Event (AKI, Ketoacidosis, Amputation, Fournier Gangrene)
Halden et al. (21) (Empa) RCT 24 25 3 (Control), 3 (Empa) (Control), (Empa) NR
Schwaiger et al. (22) (Empa) PS 14 24 9 (Ref), 5 (Empa) 1 NR
Mahling et al. (25) (Empa) CS 10 N/A 2 NR 1 (Ulcer)
Rajasekeran et al. (24) (Cana) CS 10 N/A NR NR 1 (Cellulitis)
Attallah et al. (26) (Empa/Dapa) CS 8 N/A 3 NR NR
Shah et al. (23) (Cana) PS 24 N/A NR NR NR
AlKindi et al. (27) (Dapa/Empa) RS 8 N/A 1 NR NR
kong et al. (30) (Dapa) RS 42 N/A 3 NR NR
Song et al. (28) (Empa/Cana/Dapa) RS 50 N/A 7 1 NR
Empa, empagliflozin; RCT, randomized control trial; NR, not reported; PS, prospective study; Ref, reference group; CS, case series; Cana, canagliflozin; Dapa, dapagliflozin; RS, retrospective study; N/A, no control group available.

The only RCT including patients with KT enrolled 49 patients with new-onset diabetes after transplantation who were randomized to either empagliflozin or placebo (21). This study found that after 6 months, patients in the empagliflozin group had minimal change in HbA1c, fasting plasma glucose, or 2-hour oral glucose tolerance test. Similarly, a prospective study in which eight patients with diabetes and KT were switched from insulin to empagliflozin monotherapy found higher oral glucose tolerance test results, home blood glucose levels, and HbA1c—suggesting that empagliflozin should be used as an add-on agent rather than monotherapy (22). In addition, several patient series have also shown modest changes in HbA1c with SGLT2 inhibitor use (23–27). Overall, these studies did not find significantly higher rates of infection with SGLT2 inhibitor use, although inclusion criteria were generally limited to those without a significant history of UTI or genital mycotic infections. In some cases, however, UTI did lead to SGLT2 inhibitor discontinuation. Inclusion criteria for many of these studies also selected for those patients at least 1-year post-transplantation with well-controlled diabetes and stable kidney function. Two studies (both with canagliflozin use) reported no episodes of UTI or genital infections (23,24). Thus far, there have been no reports of Fournier gangrene in patients with KT with SGLT2 inhibitor use. Apart from one study, SGLT2 inhibitors were administered at least 1 year after kidney transplantation (28).

From the only KT RCT mentioned earlier, three episodes of UTI occurred in both treatment and control arms, and one genital mycotic infection was reported in the empagliflozin group (21). This study excluded patients with a history of recurrent UTI, urosepsis, and genital mycosis. Several other studies used similar exclusion criteria, with some requiring a UTI-free period of 6 months prior to SGLT2 inhibitor initiation (23,25).

As immunosuppression is typically more intense during the first year after transplantation, the majority of reports examining the use of SGLT2 inhibitors in kidney transplantation thus far have excluded patients during this time period. The largest retrospective study to date includes 50 patients with KT (mostly on empagliflozin), half of whom were initiated on SGLT2 inhibitors within the first year of transplantation (28). In this cohort, there were no reports of AKI, amputations, or diabetic ketoacidosis. There were seven UTIs (14%), similar to the prevalence of UTI in this population without SGLT2 inhibitor use. There was a statistically significant decrease of 0.13 mg/dl in magnesium concentration, without clear clinical significance.

Because of their diuretic effect, it is not surprising that SGLT2 inhibitors may affect volume status. One study of patients with KT on empagliflozin used bioimpedance spectroscopy to show a transient loss of total body water, without significant decreases in BP (22). Similarly, the RCT did not show significant BP changes between empagliflozin and placebo groups (21). Both studies reported statistically significant weight loss in patients taking empagliflozin, averages of 1.6 kg (P=0.02) (22) and 2.5 kg (P=0.01) (21) from their baseline.

Summary and Recommendations

The antiglycemic effect of SGLT2 inhibitors in patients with KT seems to be comparable with the modest effect previously demonstrated in large RCTs in non-KT patients, although data are limited. Although long-term CV and kidney outcomes remain to be evaluated in this specific patient population, it seems probable that similar effects will be seen as in the nontransplant population given hypothesized mechanisms of CV efficacy (12). Current data in this group suggest few cases of infections; only one episode of AKI; and thus far, no reports of ketoacidosis, amputations, or Fournier gangrene. Empagliflozin and canagliflozin may be reasonable options, as they have been the most studied in the KT population within the drug class. With no current guidelines in place, we suggest that transplant nephrologists screen patients with KT on the basis of the criteria in Table 2 to assess candidacy and consider SGLT2 inhibitor prescription in select patients. Of utmost importance is the assessment for prior history of recurrent UTI and genital infections and close follow-up after initiation. BP and diuretics may require adjustment prior to SGLT2 inhibitor initiation. Like those without KT, patients with KT should also receive effective counseling prior to starting SGLT2 inhibitors, including education of SGLT2 inhibitor avoidance on “sick day rules” to lower the risk of AKI and ketoacidosis, checking of BP, maintenance of genital hygiene, and lower-extremity surveillance (29). Transplant nephrologists should wait 6–12 months immediately post-transplantation to initiate SGLT2 inhibitors. Similarly, in the setting of allograft rejection treatment, during which immunosuppression is increased, it seems prudent to delay or hold SGLT2 inhibitor use for 6-12 months. Although SGLT2 inhibitor use is growing, cost and insurance approvals have been barriers in prescribing them (26). Of course, the transplant community eagerly awaits RCTs to definitively explore efficacy and safety of this promising drug class. It remains to be seen how SGLT2 inhibitors will perform in those with pancreas transplants as well as recipients with gastroparesis and bariatric surgery. In medicine, one size has never fit all. It is time for a cautious, thoughtful, and personalized approach to select the best candidates with KT for safe SGLT2 inhibitor use to allow our patients to benefit from this shiny new tool in the nephrologist’s armamentarium.

Table 2. - Characteristics of the “ideal” sodium-glucose cotransporter 2 inhibitor candidate with a kidney transplant
Proposed Characteristics for the “Ideal” Sodium-Glucose Cotransporter 2 Inhibitor Candidate with Kidney Transplant
At least 6–12 mo after KT with stable kidney function
No recent episode of KT rejection or need for increased immunosuppression within 6–12 mo
No history of recurrent UTI or genital infection and 6-mo UTI-free period prior to initiation
No history of recurrent or persistent hypotension or recurrent episodes of volume depletion
No history of peripheral vascular disease
Stable BP
KT, kidney transplantation; UTI, urinary tract infection.


S. S. Farouk reports other interests/relationships as a member of the editorial boards of American Journal of Kidney Diseases, Clinical Transplantation, and Journal of Nephrology. The remaining authors have nothing to disclose.




The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or Kidney360. Responsibility for the information and views expressed herein lies entirely with the author(s).

Author Contributions

S. S. Farouk and N. Patel conceptualized the study; S. S. Farouk provided supervision; and S. S. Farouk, J. Hindi, and N. Patel wrote the original draft and reviewed and edited the manuscript.


1. International Diabetes Federation: IDF Diabetes Atlas, 9th Ed., Brussels, Belgium, International Diabetes Federation, 2019
2. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol 6: 148–158, 2021
3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015
4. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377: 644–657, 2017
5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380: 347–357, 2019
6. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–1446, 2020
7. Kidney Disease Outcomes Quality Initiative (K/DOQI): K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43[Suppl 1]: S1–S290, 2004
8. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–334, 2016
9. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019
10. Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B: Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 6: 691–704, 2018
11. Awan AA, Niu J, Pan JS, Erickson KF, Mandayam S, Winkelmayer WC, Navaneethan SD, Ramanathan V: Trends in the causes of death among kidney transplant recipients in the United States (1996-2014). Am J Nephrol 48: 472–481, 2018
12. Penmatsa K: SGLT2 Inhibitors and AKI: Time to Ditch the Dogma. AJKD Blog, 2020. Available at: Accessed February 2, 2021
13. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R: SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39[Suppl 2]: S165–S171, 2016
14. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ: Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis. Diabetes Obes Metab 18: 783–794, 2016
15. Fishman JA: Infection in solid-organ transplant recipients. N Engl J Med 357: 2601–2614, 2007
16. Wang T, Patel SM, Hickman A, Liu X, Jones PL, Gantz I, Koro CE: SGLT2 inhibitors and the risk of hospitalization for Fournier’s gangrene: A nested case-control study. Diabetes Ther 11: 711–723, 2020
17. Goldman JD, Julian K: Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33: e13507, 2019
18. Ariza-Heredia EJ, Beam EN, Lesnick TG, Kremers WK, Cosio FG, Razonable RR: Urinary tract infections in kidney transplant recipients: Role of gender, urologic abnormalities, and antimicrobial prophylaxis. Ann Transplant 18: 195–204, 2013
19. Menne J, Dumann E, Haller H, Schmidt BMW: Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med 16: e1002983, 2019
20. Abbott KC, Bernet VJ, Agodoa LY, Yuan CM: Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome after renal transplantation in the United States. BMC Endocr Disord 3: 1, 2003
21. Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, Bollerslev J, Hartmann A, Åsberg A, Jenssen T: Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 42: 1067–1074, 2019
22. Schwaiger E, Burghart L, Signorini L, Ristl R, Kopecky C, Tura A, Pacini G, Wrba T, Antlanger M, Schmaldienst S, Werzowa J, Säemann MD, Hecking M: Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 19: 907–919, 2019
23. Shah M, Virani Z, Rajput P, Shah B: Efficacy and safety of canagliflozin in kidney transplant patients. Indian J Nephrol 29: 278–281, 2019
24. Rajasekeran H, Kim SJ, Cardella CJ, Schiff J, Cattral M, Cherney DZI, Singh SKS: Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: A case series. Diabetes Care 40: e75–e76, 2017
25. Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M: Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 44: 984–992, 2019
26. Attallah N, Yassine L: Use of empagliflozin in recipients of kidney transplant: A report of 8 cases. Transplant Proc 51: 3275–3280, 2019
27. AlKindi F, Al-Omary HL, Hussain Q, Al Hakim M, Chaaban A, Boobes Y: Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients. Transplant Proc 52: 175–178, 2020
28. Song CC, Brown A, Winstead R, Yakubu I, Demehin M, Kumar D, Gupta G: Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients. Endocrinol Diabetes Metab 4: e00185, 2020
29. Lam D, Shaikh A: Real-life prescribing of SGLT2 inhibitors: How to handle other medications, including glucose-lowering drugs and diuretics. Kidney360 2: 742–746, 2021
30. kong j, Joon J, Chul Y, Eun W, Hyuk K, Hyun SS: Sodium/glucose cotransporter 2 inhibitor for the treatment of diabetes in kidney transplant patients. Nephrol Dial Transplant 34[Suppl 1]: gfz103.SP770, 2019

transplantation; diabetes; kidney transplant; proteinuria; SGLT2 inhibitors

Copyright © 2021 by the American Society of Nephrology